trial
as of 2026-07-01Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation
NCTId NCT00628394
at a glance
Phase 4 · Completed
Enrollment 119 (actual)
Sponsored by University of Texas Southwestern Medical Center
Primary completion 2011-02
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
119 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2003-09
Primary completion
2011-02
Eligibility
ALL · 18 Years · 60 Years
Interventions & indications
Drugs
Indications
Sponsors
University of Texas Southwestern Medical CenterLead Sponsor
National Institute of Mental Health (NIMH)Collaborator
Stanley Medical Research InstituteCollaborator
Investigators
1
Carol A Tamminga, MDPrincipal Investigator
Sites
1 total
Dallas, United States
Facts & assertions
4 sourced
Enrollment
119
Phase
PHASE4
Primary Completion Date
2011-02
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
collaborator
indication
indication
indication
investigator
person